OVERALL SURVIVAL WITH DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (ALCYONE): A RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL

A clinical trial published in The Lancet demonstrates the benefits of a new combination of drugs for the treatment of multiple myeloma. This new treatment “significantly improves the survival of newly diagnosed patients of this disease without the option of bone marrow transplantation.” The Alcyone study is a phase III clinical trial, conducted on 706 …

OVERALL SURVIVAL WITH DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (ALCYONE): A RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL Read More »